BioCentury
ARTICLE | Product R&D

Lilly’s new leaf

How Lilly’s new R&D head aims to beef up the pharma’s first-in-class cache

May 31, 2018 7:02 PM UTC

As Daniel Skovronsky takes the helm of Eli Lilly and Co.’s R&D business, his goal is to shake the pharma’s reputation as a fast-follower and instead advance first-in-class therapeutics with large effect sizes. To get there, he is pushing for more early stage collaborations, building biotech-like structures within R&D, and exploring new modalities synergistic with Lilly’s expertise.

Skovronsky will take over as SVP for science and technology and president of Lilly Research Laboratories on June 1, succeeding Jan Lundberg, who is retiring. Skovronsky was previously SVP for clinical and product development and joined Lilly in 2010 when the pharma acquired Avid Radiopharmaceuticals Inc...

BCIQ Company Profiles

Eli Lilly and Co.

BCIQ Target Profiles

Beta amyloid